CN115353860A - Medical endoscope antifogging agent - Google Patents
Medical endoscope antifogging agent Download PDFInfo
- Publication number
- CN115353860A CN115353860A CN202211158953.1A CN202211158953A CN115353860A CN 115353860 A CN115353860 A CN 115353860A CN 202211158953 A CN202211158953 A CN 202211158953A CN 115353860 A CN115353860 A CN 115353860A
- Authority
- CN
- China
- Prior art keywords
- sodium
- agent
- antifogging agent
- medical
- sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 25
- 239000004094 surface-active agent Substances 0.000 claims abstract description 5
- 239000000463 material Substances 0.000 claims abstract description 3
- 239000003755 preservative agent Substances 0.000 claims abstract description 3
- 230000002335 preservative effect Effects 0.000 claims abstract description 3
- 239000002904 solvent Substances 0.000 claims abstract description 3
- 239000002562 thickening agent Substances 0.000 claims abstract description 3
- 239000000080 wetting agent Substances 0.000 claims abstract description 3
- 239000011248 coating agent Substances 0.000 claims abstract 2
- 238000000576 coating method Methods 0.000 claims abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 13
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 claims description 11
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 11
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 11
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 11
- 229920000570 polyether Polymers 0.000 claims description 11
- 229920000223 polyglycerol Polymers 0.000 claims description 11
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 11
- 235000010234 sodium benzoate Nutrition 0.000 claims description 11
- 239000004299 sodium benzoate Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- LGNQGTFARHLQFB-UHFFFAOYSA-N 1-dodecyl-2-phenoxybenzene Chemical compound CCCCCCCCCCCCC1=CC=CC=C1OC1=CC=CC=C1 LGNQGTFARHLQFB-UHFFFAOYSA-N 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 239000008367 deionised water Substances 0.000 claims description 9
- 229910021641 deionized water Inorganic materials 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 7
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 7
- 229940051841 polyoxyethylene ether Drugs 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940057950 sodium laureth sulfate Drugs 0.000 claims description 4
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 claims description 4
- 230000002195 synergetic effect Effects 0.000 claims description 4
- OJLOUXPPKZRTHK-UHFFFAOYSA-N dodecan-1-ol;sodium Chemical compound [Na].CCCCCCCCCCCCO OJLOUXPPKZRTHK-UHFFFAOYSA-N 0.000 claims description 3
- ZIWRUEGECALFST-UHFFFAOYSA-M sodium 4-(4-dodecoxysulfonylphenoxy)benzenesulfonate Chemical compound [Na+].CCCCCCCCCCCCOS(=O)(=O)c1ccc(Oc2ccc(cc2)S([O-])(=O)=O)cc1 ZIWRUEGECALFST-UHFFFAOYSA-M 0.000 claims description 2
- 239000000306 component Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 241000282887 Suidae Species 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000008358 core component Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 235000011837 pasties Nutrition 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002674 endoscopic surgery Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000569 greater omentum Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K3/00—Materials not provided for elsewhere
- C09K3/18—Materials not provided for elsewhere for application to surfaces to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
Abstract
The invention discloses a medical endoscope antifogging agent, which relates to the technical field of antifogging agents and aims to solve the problem that no suitable endoscope antifogging agent suitable for operation is available at present, and the medical endoscope antifogging agent comprises the following components in parts by weight: the coating comprises a surfactant, a thickening agent, a wetting agent, a preservative and a solvent, wherein all the components are food-grade materials.
Description
Technical Field
The invention relates to the technical field of antifogging agents, in particular to a medical endoscope antifogging agent.
Background
In the clinical process of medicine, lens fogging is a common phenomenon in the process of using an endoscope for surgery or examination, and diagnosis and treatment efficiency is influenced. At present, the average fogging time of an endoscope used by a medical institution is 4-6 minutes, the operation time of one surgical endoscope is about 26-90 minutes, several hours can be reached in individual complex operations, the endoscope needs to be drawn out to repeatedly wipe the fog during each operation, and the progress and the smoothness of the operation are seriously influenced. The widely popular practice at present is as follows: a hot water preheating method for a lens, a tissue omentum majus wiping method and an iodophor wiping method (the method has low cost and convenient operation and is used more). Although antifogging agents are available on the market, the antifogging agents are not suitable for in vivo use due to toxicity, that is, no suitable endoscope antifogging agent suitable for surgical operation is available at present.
Disclosure of Invention
The invention provides a medical endoscope antifogging agent, which comprises: the food-grade detergent comprises a surfactant, a thickening agent, a wetting agent, a preservative and a solvent, wherein all the components are food-grade materials.
The invention is further configured as follows: the surfactant comprises at least one of fluorocarbon, sodium laureth sulfate, dioctyl sodium sulfosuccinate, sodium dodecyl sulfate and dodecyl diphenyl ether disulfonate.
The invention is further provided with: the components comprise: fluorocarbon, sodium chloride, sodium laureth sulfate, alkynol polyether, polyethylene glycol, dioctyl sodium sulfosuccinate, sodium dodecyl sulfate, dodecyl diphenyl ether disulfonate, sodium benzoate and deionized water.
The invention is further configured as follows: the antibacterial agent also comprises a synergistic antibacterial agent which is polyglycerol ester.
The invention is further provided with: the components are respectively as follows by mass percent: 44% -47% of fluorocarbon, 0.8% -1.3% of sodium chloride, 4.5% -6.5% of sodium lauryl polyoxyethylene ether sulfate, 4.5% -5.5% of alkynol polyether, 1.4% -1.6% of polyethylene glycol, 0.3% -0.5% of dioctyl sodium sulfosuccinate, 0.4% -0.6% of sodium dodecyl sulfate, 0.3% -0.5% of dodecyl diphenyl ether disulfonate, 0.2% -0.4% of sodium benzoate, 3.5% -4.5% of polyglycerol ester, 31% -36% of deionized water, essence: and (4) the balance.
The invention has the beneficial effects that:
the core component in the formula of the invention is the mixture of fluorocarbon, alkynol polyether, sodium benzoate and polyglycerol ester, the four components have synergistic effect, and under a specific proportion, the composite material has extremely strong hydrophobicity and oleophobicity, and can ensure that the endoscope head can keep clear for a long time in the using process.
Detailed Description
Preferred embodiments of the present invention are described below. It should be understood by those skilled in the art that these embodiments are only for explaining the technical principle of the present invention, and are not intended to limit the scope of the present invention.
Example 1
The antifogging agent for the medical endoscope provided by the embodiment is prepared by 100g of samples, and comprises the following components in parts by weight: 45% of fluorocarbon, 1.2% of sodium chloride, 6.1% of sodium lauryl alcohol polyoxyethylene ether sulfate, 5.2% of alkynol polyether, 1.5% of polyethylene glycol, 0.4% of dioctyl sodium sulfosuccinate, 0.5% of sodium dodecyl sulfate, 0.5% of dodecyl diphenyl ether disulfonate, 0.4% of sodium benzoate, 4.5% of polyglycerol ester, 34% of deionized water, and essence: and (4) the balance.
The components are required to be food grade.
Comparative experiment 1
The experimental site is as follows: peking market valley animal simulation hospital
Experimental animals: piglet
For experimental review: according to the similarity, reliability and economic principle, the young pig with the body temperature close to that of human is selected as an experimental object, and the experiment is carried out by utilizing the opportunity of regular training of uterus and laparoscope operations of gynecology, urology surgery and the like of doctors from hospitals in various provinces and cities in China by using a simulation hospital.
Experiment design: 3 simulated operating rooms are prepared, and two sets of endoscopic surgery equipment are respectively arranged in each simulated operating room. 6 young pigs were randomly selected and numbered 1-6 one by one. Using three young pigs numbered as No. 1, no. 2 and No. 3 as a control group, and wiping the endoscope lens by iodophor; three young pigs, no. 4, no. 5, and No. 6, were used as experimental groups, and the medical endoscope antifogging agent wiping lens of example 1 was used.
The experimental process comprises the following steps: the simulated operating room temperature was 22 ℃ and the expected time of anesthesia for the young pigs was 90 minutes, and medical staff wiped the lenses with iodophor and the medical endoscopic antifogging agent of example 1, respectively, during which time the in vivo tissues of the pigs were electrically stripped and cut using monopolar and bipolar probes, respectively. If the young pig has the evidence of waking up, a small dose of anesthesia is added, and meanwhile, a doctor completes the operation as soon as possible; recording the time of the fogging phenomenon of the endoscope lens caused by the high-temperature and high-humidity internal environment of the pig body in the process, wiping the lens and smearing a corresponding reagent after recording, and restarting recording for 10 times in total.
Fog evaluation standard: the common experience of judging the fogging of the endoscope lens in clinic is that one fourth of the area seen in the visual field is pasty or only a little pasty appears in the central part, namely the fogging is formed.
The experimental data are as follows:
through data comparison, the antifogging agent of the medical endoscope in the embodiment can be obviously improved in antifogging time.
Example 2
The antifogging agent for the medical endoscope provided by the embodiment is prepared by 100g of samples, and comprises the following components in parts by weight: 44% of fluorocarbon, 1.2% of sodium chloride, 6.1% of sodium lauryl polyoxyethylene ether sulfate, 5.2% of alkynol polyether, 1.5% of polyethylene glycol, 0.4% of dioctyl sodium sulfosuccinate, 0.5% of sodium dodecyl sulfate, 0.5% of dodecyl diphenyl ether disulfonate, 0.4% of sodium benzoate, 4.5% of polyglycerol ester, 35% of deionized water, and essence: and (4) the balance.
Example 3
The antifogging agent for the medical endoscope provided by the embodiment is prepared by 100g of samples, and comprises the following components in parts by weight: 47% of fluorocarbon, 1.2% of sodium chloride, 6.1% of sodium lauryl alcohol polyoxyethylene ether sulfate, 5.2% of alkynol polyether, 1.5% of polyethylene glycol, 0.4% of dioctyl sodium sulfosuccinate, 0.5% of sodium dodecyl sulfate, 0.5% of dodecyl diphenyl ether disulfonate, 0.4% of sodium benzoate, 4.5% of polyglycerol ester, 32% of deionized water, and essence: and the balance.
Comparative example 1
The medical endoscope antifogging agent provided by the comparative example is prepared into 100g of samples, and comprises the following components in parts by weight: 47% of fluorocarbon, 1.2% of sodium chloride, 6.1% of sodium lauryl polyoxyethylene ether sulfate, 0% of alkynol polyether, 1.5% of polyethylene glycol, 0.4% of dioctyl sodium sulfosuccinate, 0.5% of sodium dodecyl sulfate, 0.5% of dodecyl diphenyl ether disulfonate, 0% of sodium benzoate, 0% of polyglycerol ester, 42.1% of deionized water, essence: and the balance.
Comparative example 2
The antifogging agent for the medical endoscope provided by the embodiment is prepared by 100g of samples, and comprises the following components in parts by weight: 0% of fluorocarbon, 1.3% of sodium chloride, 6.5% of sodium lauryl polyoxyethylene ether sulfate, 5.5% of alkynol polyether, 1.6% of polyethylene glycol, 0.5% of dioctyl sodium sulfosuccinate, 0.6% of sodium dodecyl sulfate, 0.5% of dodecyl diphenyl ether disulfonate, 0.4% of sodium benzoate, 4.5% of polyglycerol ester, 78% of deionized water, and essence: and the balance.
Comparative experiment 2
Referring to comparative experiment 1, 5 young pigs were selected, the reagents prepared in examples 1 to 3 and comparative examples 1 to 2 were applied to the endoscope head, and the fogging time was recorded during the simulated surgery teaching, eight times for each reagent.
The experimental data are shown in Table 2
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | |
| Example 1 | 32 | 34 | 35 | 33 | 37 | 37 | 36 | 37 |
| Example 2 | 31 | 27 | 27 | 29 | 32 | 30 | 30 | 32 |
| Example 3 | 21 | 19 | 24 | 23 | 21 | 20 | 19 | 20 |
| Comparative example 1 | 12 | 10 | 13 | 12 | 9 | 11 | 14 | 12 |
| Comparative example 2 | 11 | 9 | 9 | 12 | 11 | 10 | 10 | 11 |
According to the data, the core component in the formula of the invention is the mixture of fluorocarbon, alkynol polyether, sodium benzoate and polyglycerol ester, the four components have synergistic effect, and under a specific proportion, the composition has extremely strong hydrophobicity and oleophobicity, and can ensure that the endoscope lens can keep clear for a long time in the using process. Moreover, the effects of the four ingredients also need to be better achieved by a stricter proportion.
While the invention has been described with reference to a preferred embodiment, various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention, and particularly, features shown in the various embodiments may be combined in any suitable manner without departing from the scope of the invention. It is intended that the invention not be limited to the particular embodiments disclosed, but that the invention will include all embodiments falling within the scope of the appended claims.
Claims (5)
1. An antifogging agent for medical use, comprising: the coating comprises a surfactant, a thickening agent, a wetting agent, a preservative and a solvent, wherein all the components are food-grade materials.
2. The medical antifogging agent for endoscope according to claim 1, characterized in that: the surfactant comprises at least one of fluorocarbon, sodium laureth sulfate, dioctyl sodium sulfosuccinate, sodium dodecyl sulfate and dodecyl diphenyl ether disulfonate.
3. The medical antifogging agent of claim 2, comprising the components of: fluorocarbon, sodium chloride, sodium laureth sulfate, alkynol polyether, polyethylene glycol, dioctyl sodium sulfosuccinate, sodium dodecyl sulfate, dodecyl diphenyl ether disulfonate, sodium benzoate and deionized water.
4. The medical antifogging agent for endoscope according to claim 3, characterized in that: the antibacterial agent also comprises a synergistic antibacterial agent which is polyglycerol ester.
5. The medical antifogging agent for endoscopes according to claim 4, characterized in that the components contained in the antifogging agent are, by mass percent: 44% -47% of fluorocarbon, 0.8% -1.3% of sodium chloride, 4.5% -6.5% of sodium lauryl alcohol polyoxyethylene ether sulfate, 4.5% -5.5% of alkynol polyether, 1.4% -1.6% of polyethylene glycol, 0.3% -0.5% of dioctyl sodium sulfosuccinate, 0.4% -0.6% of sodium dodecyl sulfate, 0.3% -0.5% of dodecyl diphenyl ether disulfonate, 0.2% -0.4% of sodium benzoate, 3.5% -4.5% of polyglycerol ester, 31% -36% of deionized water, and essence: and the balance.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211158953.1A CN115353860B (en) | 2022-09-22 | 2022-09-22 | Medical endoscope antifogging agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211158953.1A CN115353860B (en) | 2022-09-22 | 2022-09-22 | Medical endoscope antifogging agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115353860A true CN115353860A (en) | 2022-11-18 |
| CN115353860B CN115353860B (en) | 2024-01-02 |
Family
ID=84007336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211158953.1A Active CN115353860B (en) | 2022-09-22 | 2022-09-22 | Medical endoscope antifogging agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115353860B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6296694B1 (en) * | 1998-06-25 | 2001-10-02 | Roger Machson | Transparent anti-fog anti-splash coating compositions |
| CN104477139A (en) * | 2014-12-23 | 2015-04-01 | 扬州倍加洁日化有限公司 | Automobile glass cleaning and defrosting antifogging wet tissue and processing method thereof |
| CN106833524A (en) * | 2016-12-28 | 2017-06-13 | 于文 | Glass pane antifoggant and preparation method thereof in automobile |
| CN111196916A (en) * | 2018-11-20 | 2020-05-26 | 上海昕光医疗科技有限公司 | Medical antifogging agent and preparation method thereof |
| CN111574960A (en) * | 2020-05-12 | 2020-08-25 | 浙江优亿医疗器械有限公司 | Formula and preparation method of antifogging liquid |
| CN111592856A (en) * | 2020-05-08 | 2020-08-28 | 南京普莱斯医疗器材有限公司 | Visual field clearing agent for medical endoscope and preparation method thereof |
| CN113105868A (en) * | 2021-04-19 | 2021-07-13 | 江苏南创化学与生命健康研究院有限公司 | Antibacterial antifogging agent and antibacterial long-acting antifogging wet tissue prepared from same |
-
2022
- 2022-09-22 CN CN202211158953.1A patent/CN115353860B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6296694B1 (en) * | 1998-06-25 | 2001-10-02 | Roger Machson | Transparent anti-fog anti-splash coating compositions |
| CN104477139A (en) * | 2014-12-23 | 2015-04-01 | 扬州倍加洁日化有限公司 | Automobile glass cleaning and defrosting antifogging wet tissue and processing method thereof |
| CN106833524A (en) * | 2016-12-28 | 2017-06-13 | 于文 | Glass pane antifoggant and preparation method thereof in automobile |
| CN111196916A (en) * | 2018-11-20 | 2020-05-26 | 上海昕光医疗科技有限公司 | Medical antifogging agent and preparation method thereof |
| CN111592856A (en) * | 2020-05-08 | 2020-08-28 | 南京普莱斯医疗器材有限公司 | Visual field clearing agent for medical endoscope and preparation method thereof |
| CN111574960A (en) * | 2020-05-12 | 2020-08-25 | 浙江优亿医疗器械有限公司 | Formula and preparation method of antifogging liquid |
| CN113105868A (en) * | 2021-04-19 | 2021-07-13 | 江苏南创化学与生命健康研究院有限公司 | Antibacterial antifogging agent and antibacterial long-acting antifogging wet tissue prepared from same |
Non-Patent Citations (1)
| Title |
|---|
| 张天胜: "《表面活性剂应用技术》", vol. 1, 化学工业出版社, pages: 224 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115353860B (en) | 2024-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yoshimura et al. | A comparison of three methods used for treatment of ranula | |
| Lowenstein et al. | Robotic transvaginal natural orifice transluminal endoscopic surgery for bilateral salpingo oophorectomy | |
| Chang et al. | Limited distal sialodochotomy to facilitate sialendoscopy of the submandibular duct. | |
| CN104382842A (en) | Endoscopic anesthesia gel preparation and application thereof | |
| Li et al. | Robot-assisted partial nephrectomy with the newly developed kangduo surgical robot versus the da vinci si surgical system: a double-center prospective randomized controlled noninferiority trial | |
| Yadav et al. | Practical aspects of neuroendoscopic techniques and complication avoidance: a systematic review | |
| Szabo et al. | Intraorbital penetrating and retained foreign bodies-a neurosurgical case series | |
| CN115353860B (en) | Medical endoscope antifogging agent | |
| Sánchez‐Margallo et al. | Preliminary application of a single‐port access technique for laparoscopic ovariohysterectomy in dogs | |
| Regmi et al. | Endoscopic endonasal transsphenoidal approach to pituitary adenoma: A multi-disciplinary approach | |
| Tan et al. | Endoscopic transnasal approach to medial orbital lesions | |
| Martinez et al. | Transfer of acquired practical skills from dry lab into live surgery using the avatera robotic system: An experimental study | |
| Zhang et al. | Pros and cons of transoral endoscopic thyroidectomy via vestibular approach: a comparative study | |
| Kondo et al. | Diagnostic and treatment effects of sialendoscopy for patients with swelling of the parotid gland when sialoliths are undetected with computed tomography | |
| Bain et al. | Endoscopic excision of supracondylar humeral spur for decompression of the median nerve and brachial artery | |
| White | Registry of laparoscopic cholecystectomy and new and evolving laparoscopic techniques | |
| Kaya et al. | Endobronchial hamartoma removed by flexible fiberoptic bronchoscopy via electrocautery | |
| Cevrioglu et al. | Assessment of endocervical and endometrial damage inflicted by embryo transfer trial: a hysteroscopic evaluation | |
| Taylor | Endoscopic diagnosis of avian respiratory tract diseases | |
| Taylor | A new endoscopic system for the collection of diagnostic specimens in the bird | |
| Hawkes et al. | Improving Techniques to Study Equine Cervical Mucociliary Clearance | |
| Ford et al. | Diagnostic and therapeutic procedures | |
| Fani | Abstracts of the joint ALLSA, SATS and CWIG Congress in Pretoria, July 2019 | |
| Yalcin et al. | Pneumatic lithotripter application for giant bladder stone in a patient with augmentation cystoplasty | |
| Maitiyasen et al. | Robot-Assisted Thoracic Surgery for benign tumors at the cervicothoracic junction: A retrospective study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |